TWI332833B - New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors - Google Patents

New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors Download PDF

Info

Publication number
TWI332833B
TWI332833B TW091104144A TW91104144A TWI332833B TW I332833 B TWI332833 B TW I332833B TW 091104144 A TW091104144 A TW 091104144A TW 91104144 A TW91104144 A TW 91104144A TW I332833 B TWI332833 B TW I332833B
Authority
TW
Taiwan
Prior art keywords
micrograms
present
inhalable powder
powder composition
salt
Prior art date
Application number
TW091104144A
Other languages
English (en)
Chinese (zh)
Inventor
Pairet Michel
John Montague Meade Christopher
P Pieper Michael
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of TWI332833B publication Critical patent/TWI332833B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW091104144A 2001-03-07 2002-03-06 New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors TWI332833B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10110772A DE10110772A1 (de) 2001-03-07 2001-03-07 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren

Publications (1)

Publication Number Publication Date
TWI332833B true TWI332833B (en) 2010-11-11

Family

ID=7676493

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091104144A TWI332833B (en) 2001-03-07 2002-03-06 New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors

Country Status (18)

Country Link
EP (1) EP1372649B1 (https=)
JP (1) JP2004521134A (https=)
KR (1) KR20030081501A (https=)
CN (1) CN1649588A (https=)
AR (1) AR034213A1 (https=)
AU (1) AU2002257587B2 (https=)
BR (1) BR0207883A (https=)
CA (1) CA2439763C (https=)
CZ (1) CZ20032635A3 (https=)
DE (1) DE10110772A1 (https=)
EA (1) EA009989B1 (https=)
HU (1) HUP0400782A3 (https=)
IL (2) IL157326A0 (https=)
MX (1) MXPA03008045A (https=)
NZ (1) NZ528621A (https=)
PL (1) PL363078A1 (https=)
TW (1) TWI332833B (https=)
WO (1) WO2002069945A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2002096423A2 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
DK1610787T3 (da) * 2003-03-28 2008-06-02 Nycomed Gmbh Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
WO2004084897A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
WO2005013967A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
EP1504756A1 (en) * 2003-08-06 2005-02-09 Kyowa Hakko Kogyo Co., Ltd Medicament compositions comprising a heterocyclic compound and an anticholinergic
CA2547394A1 (en) * 2004-01-09 2005-07-28 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on a scopineester and nicotinamide derivatives
EP1713473B1 (en) 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
WO2005074982A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
JP2007524699A (ja) * 2004-02-27 2007-08-30 アルタナ ファルマ アクチエンゲゼルシャフト ロフルミラストとグリコピロニウムとの組合せ物
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
ES2570332T3 (es) 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
NZ591969A (en) 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
SI2046787T1 (sl) 2006-08-01 2011-07-29 Glaxo Group Ltd Pirazolo(3,4-b)piridinske spojine in njihova uporaba kot PDE4 inhibitorji
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2010219097A1 (en) 2009-01-13 2011-08-04 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102670607A (zh) * 2012-05-28 2012-09-19 海南卫康制药(潜山)有限公司 复方盐酸氨溴索组合物及其制备方法
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
WO2014191826A1 (en) * 2013-05-31 2014-12-04 Nexpath Medical Sa Acetabular reamer assembly

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
EE200200426A (et) * 2000-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid
CA2404226A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito

Also Published As

Publication number Publication date
WO2002069945A2 (de) 2002-09-12
PL363078A1 (en) 2004-11-15
DE10110772A1 (de) 2002-09-12
WO2002069945A3 (de) 2003-01-30
EA009989B1 (ru) 2008-04-28
NZ528621A (en) 2005-04-29
JP2004521134A (ja) 2004-07-15
KR20030081501A (ko) 2003-10-17
CZ20032635A3 (cs) 2004-09-15
EP1372649A2 (de) 2004-01-02
HUP0400782A3 (en) 2012-09-28
IL157326A (en) 2011-12-29
CN1649588A (zh) 2005-08-03
AU2002257587B2 (en) 2007-05-10
MXPA03008045A (es) 2003-12-04
HUP0400782A2 (hu) 2004-07-28
CA2439763C (en) 2012-10-16
EA200300929A1 (ru) 2004-04-29
AR034213A1 (es) 2004-02-04
IL157326A0 (en) 2004-02-19
CA2439763A1 (en) 2002-09-12
EP1372649B1 (de) 2012-07-25
BR0207883A (pt) 2004-07-27

Similar Documents

Publication Publication Date Title
TWI332833B (en) New pharmaceutical compositions based on anticholinergics and pde-iv inhibitors
JP4537652B2 (ja) 抗コリン作用薬及びシクレソニドをベースとする新規薬剤組成物
US20040024007A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
JP4282594B2 (ja) チオトロピウム塩及びサルメテロール塩に基づく新規医薬組成物
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
CA2733294C (en) Pharmaceutical combination of a tiotropium salt and ciclesonide
US20040058950A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
JP2004528305A (ja) 炎症性疾患を治療するための化合物
US20040192675A1 (en) Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
WO2004024156A1 (en) Tiotropium salts for reducing respiratory mortality rate
US20040161386A1 (en) Pharmaceutical compositions based on anticholinergic and dopamine agonists
TW200406209A (en) Medicament combinations comprising heterocyclic compounds and a novel anticholinergic
CA2629074A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
TW200303866A (en) New medicament compositions comprising besides anticholinergics heterocyclic compounds
AU2002221738B2 (en) Inhalative solution formulation containing a tiotropium salt
JP2004512379A (ja) 新規医薬組成物
ZA200306221B (en) Novel medicament compositions on the basis of anti-cholinergics and PDE IV inhibitors.
JP2004525920A (ja) 抗コリン作動薬及びエンドテリンアンタゴニストを主成分とする新規薬剤組成物
CA2430592C (en) New pharmaceutical compositions based on anticholinergics and dopamine agonists
JP4850415B2 (ja) 吸入用チオトロピウム含有医薬品組成物
TW200307550A (en) Medicaments comprising BETAMIMETICS and a novel anticholinergic
CA2614631C (en) Pharmaceutical compositions based on anticholinergics and corticosteroids in the form of an inhalable solution or suspension